Vanguard®
Vanguard® PRIMECAP Core Fund
Product Summary Vanguard Style View : Large Blend
Multi-cap equity, investing in a broad spectrum of stocks covering Diversified multi-cap portfolio of growth and value stocks across industry sectors. both growth and value stocks and a range of industries. Investment style Seeks long-term capital appreciation. Value Blend Growth Invests in out-of-favor companies at attractive valuations. Large Fundamental, research-driven stock selection process.
The managers develop separate subportfolios. Mid Note: This fund is closed to new investors. Small Market capitalizationMarket
Central tendency Expected range of fund holdings
Quarterly Commentary
The human toll of COVID-19 further mounted during the second People and Process quarter of 2021 amid fresh outbreaks of the virus and new variants. The global economy nevertheless continued to rebound Vanguard PRIMECAP Core Fund seeks to provide long-term capital sharply if unevenly. Countries that have better succeeded in appreciation through investments in companies at attractive containing the virus—whether through vaccinations, lockdowns, or valuation levels. The fund employs a fundamental, research-driven both—tended to fare the best. With the reopening of economies approach in seeking to identify companies with long-term potential and pent-up demand boosting corporate profits, global stocks overlooked by the market. The fund has the flexibility to invest finished the quarter significantly higher. U.S. stocks outperformed across all industry sectors and market capitalizations. Each other developed markets as a whole as well as emerging markets. portfolio manager independently manages a portion of the fund, searching out stocks that offer a balance between reasonable The broad U.S. stock market returned 8.24% for the quarter, as valuations and attractive earnings-growth prospects. measured by the Russell 3000 Index. Small-capitalization stocks, after a strong first quarter of the year, fell behind in the second, with the Russell 2000 Index (+4.29%) trailing its Russell 1000 PRIMECAP Management Company Index (+8.54%) counterpart. Similarly, the value rotation at the start of the year faltered, as the Russell 3000 Growth Index Founded in 1983, PRIMECAP Management Company, Pasadena, (+11.38%) outperformed the Russell 3000 Value Index (+5.16%) California, is recognized for its long-term approach to growth by a wide margin. equity investing. The firm has advised Vanguard PRIMECAP Core Fund since 2004. For the quarter, Vanguard PRIMECAP Core Fund underperformed its benchmark, the MSCI US Prime Market 750 Index (+8.75%), Investment Manager Biographies and the average return of its peers (+7.42%). Poor security selection in information technology detracted most from Joel P. Fried, President. Portfolio manager. Advised the fund since performance. Selection within industrials and consumer 2004. Worked in investment management since 1985. B.S., discretionary, notably an overweight to Southwest Airlines (–13%), University of California, Los Angeles. M.B.A., Anderson Graduate also detracted. Health care firms Eli Lilly (+23%), Biogen (+24%), School of Business, University of California, Los Angeles. and AstraZeneca (20%) added to relative performance. Overall Theo A. Kolokotrones, Chairman. Portfolio manager. Advised the sector positioning had a muted effect on returns. fund since 2004. Worked in investment management since 1970. For the 12 months ended June 30, the fund outperformed its B.A., University of Chicago. M.B.A., Harvard Business School. benchmark (+42.86%) and its peer group average (+41.95%). Ten Alfred W. Mordecai, Executive Vice President. Portfolio manager. of 11 sectors boosted relative returns. Strong security selection Advised the fund since 2004. Worked in investment management within information technology and industrials contributed most to since 1997. B.S.E., Duke University. M.E.A., Virginia Polytechnic outperformance. A significant underweight to consumer staples, Institute and State University. M.B.A., Harvard Business School. as well as selection in financials and consumer discretionary, also contributed. Health care positioning and selection detracted, M. Mohsin Ansari, Executive Vice President. Portfolio manager. specifically among pharmaceutical and biotech companies. Top Advised the fund since 2007. Worked in investment management contributors included overweight allocations to FedEx (+115%), since 2000. B.A., Colgate University. B.S., Washington University. Applied Materials (+138%), and KLA (+69%). M.B.A., Harvard Business School.
James M. Marchetti, Senior Vice President. Portfolio manager. Advised the fund since 2015. Worked in investment management Note: Company returns may differ if a security was held in the since 2005. B.A., Massachusetts Institute of Technology. M.B.A., portfolio for less than the full period. MIT Sloan School of Management.
As of June 30, 2021 Vanguard PRIMECAP Core Fund
Total Returns
Expense Year Ratio Quarter to Date 1 Year 3 Years 5 Years 10 Years PRIMECAP Core Fund (12/9/2004) 0.46% 6.30% 19.43% 48.97% 17.05% 18.25% 14.99% MSCI US Prime Market 750 Index — 8.75 14.90 42.86 19.36 18.15 15.00 Multi-Cap Core Funds Average — 7.42 14.90 41.95 15.59 15.21 11.91
The performance data shown represent past performance, which is not a guarantee of future results. Investment returns and principal value will fluctuate, so investors’ shares, when sold, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data cited. For performance data current to the most recent month-end, visit our website at vanguard.com/performance. Figures for periods of less than one year are cumulative returns. All other figures represent average annual returns. Performance figures include the reinvestment of all dividends and any capital gains distributions. All returns are net of expenses.
Note: Average fund returns are derived from data provided by Lipper, a Thomson Reuters Company.
As of June 30, 2021 Vanguard PRIMECAP Core Fund
Quarterly Returns
Year-End MSCI US PRIMECAP Prime Market Assets Year 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter Core Fund 750 Index (Millions) 2021 12.35% 6.30% — — — — $12,143 2020 -23.07 16.81 7.93% 15.57% 12.09% 21.26% 10,658 2019 10.85 2.89 1.46 10.34 27.70 31.65 11,528 2018 -0.19 1.56 9.72 -14.50 -4.90 -4.61 9,730 2017 7.44 5.25 4.98 6.33 26.23 21.97 10,690 2016 -0.43 0.14 8.62 3.73 12.35 11.72 8,623 2015 1.85 -2.18 -6.03 7.82 0.94 1.22 7,740 2014 5.20 4.60 2.24 6.03 19.29 13.58 7,328 2013 13.19 3.20 6.94 8.98 36.14 32.83 6,168 2012 9.27 -3.93 5.79 3.17 14.57 16.18 4,652 2011 5.16 0.97 -15.39 10.36 -0.86 1.65 4,628
Fund Facts Volatility Measures Fund Number 1220 R-Squared Beta Ticker VPCCX MSCI US Prime Market 750 Index 0.92 0.98 Newspaper Listing PrmcpCor DJ US Total Stock Mkt Float Adj Idx 0.93 0.97 CUSIP Number 921921508 R-squared and beta are calculated from trailing 36-month fund returns Assets (millions) $12,143 relative to the associated benchmark. Inception 12/9/2004 Expense Ratio (as of 1/2021) 0.46% Top 10 Largest Holdings
% of Total Net Assets Equity Characteristics Eli Lilly & Co. 4.8% MSCI US Prime Alphabet Inc. 3.5 PRIMECAP Market Biogen Inc. 3.2 Core Fund 750 Index Microsoft Corp. 3.2 Number of stocks 163 760 Southwest Airlines Co. 3.0 Median market cap $126.6 Billion $149.2 Billion Amgen Inc. 2.9 Average market cap $264.7 Billion $497.8 Billion AstraZeneca plc 2.8 Price/earnings ratio 23.8x 27.2x Texas Instruments Inc. 2.7 Price/book ratio 4.2x 4.5x Siemens AG 2.1 Return on equity 17.4% 19.8% FedEx Corp. 2.1 Earnings growth rate 13.1% 19.0% Total 30.3% Equity yield (dividend) 1.1% 1.3% The holdings listed exclude any temporary cash investments and equity Foreign holdings 13.8% 0.0% index products. Short-term reserves 3.2% — Turnover rate (fiscal year end) 7.5% —
As of June 30, 2021 Vanguard PRIMECAP Core Fund
Sector Diversification (% of Stocks)
MSCI US PRIMECAP Prime Market Overweight/ Core Fund 750 Index Underweight
Communication Services 6.4% 11.1% -4.7
Consumer Discretionary 12.3 12.1 0.2
Consumer Staples 0.5 5.6 -5.1
Energy 1.7 2.6 -0.9
Financials 10.2 10.9 -0.7
Health Care 25.0 13.1 11.9
Industrials 16.6 8.8 7.8
Information Technology 25.8 27.9 -2.1
Materials 1.4 2.6 -1.2
Other 0.0 0.0 0.0
Real Estate 0.1 2.9 -2.8
Utilities 0.0 2.4 -2.4 Total 100.0% 100.0% Sector categories are based on the Global Industry Classification Standard (GICS), except for the Other category (if applicable), which includes securities that have not been provided a GICS classification as of the effective reporting period.
3 month attribution Portfolio Benchmark Attribution
Avg. 3 mo. Contrib. Avg. 3 mo. Contrib. Alloc. Select Total weight return Return weight return Return effect effect effect Health Care 23.2 13.9 3.1 13.1 9.1 1.2 0.0 1.0 1.0 Consumer Staples 0.5 0.4 0.0 5.8 3.7 0.2 0.3 0.0 0.2 Financials 9.8 10.3 1.0 11.1 8.7 1.0 0.0 0.2 0.2 Utilities 0.0 0.0 0.0 2.5 -0.4 0.0 0.2 0.0 0.2 Materials 1.4 8.2 0.1 2.8 4.6 0.1 0.0 0.0 0.1 Communication Services 6.1 13.9 0.8 11.0 11.1 1.2 -0.1 0.1 0.0 Energy 1.6 6.8 0.1 2.6 11.4 0.3 0.0 -0.1 -0.1 Real Estate 0.1 14.1 0.0 2.9 12.7 0.4 -0.1 0.0 -0.1 Cash 3.6 0.0 0.0 0.0 0.0 0.0 -0.2 0.0 -0.2 Consumer Discretionary 12.1 0.1 0.0 12.2 6.8 0.8 0.0 -0.8 -0.8 Industrials 16.7 -0.8 -0.1 9.0 4.6 0.4 -0.3 -0.9 -1.2 Information Technology 24.9 5.0 1.3 27.2 11.7 3.2 -0.1 -1.6 -1.7 Total 100.0 6.4 6.4 100.0 8.8 8.8 -0.3 -2.0 -2.3
As of June 30, 2021 Vanguard PRIMECAP Core Fund
12 month attribution Portfolio Benchmark Attribution Avg. 12 mo. Contrib. Avg. 12 mo. Contrib. Alloc. Select Total weight return Return weight return Return effect effect effect Information Technology 26.4 55.4 14.7 27.7 42.6 11.8 0.0 2.9 3.0 Industrials 16.4 65.0 10.4 8.6 49.8 4.2 0.6 2.2 2.8 Financials 8.9 81.5 6.5 10.2 61.6 5.7 0.1 1.4 1.5 Consumer Discretionary 11.9 60.7 7.3 12.3 48.3 5.9 0.0 1.3 1.3 Consumer Staples 0.3 25.8 0.1 6.1 23.7 1.6 1.1 0.1 1.1 Utilities 0.0 0.0 0.0 2.7 15.3 0.5 0.7 0.0 0.7 Materials 1.3 89.6 1.1 2.7 47.9 1.3 0.0 0.6 0.5 Real Estate 0.1 33.8 0.0 2.9 32.4 0.9 0.4 0.1 0.5 Energy 1.4 62.8 0.7 2.3 49.6 1.0 0.1 0.2 0.4 Communication Services 6.2 58.5 3.5 10.8 51.1 5.3 -0.3 0.4 0.1 Cash 1.5 0.1 0.0 0.0 0.0 0.0 -0.6 0.0 -0.6 Health Care 25.6 26.2 6.5 13.7 29.0 4.2 -1.7 -1.5 -3.2 Total 100.0 50.7 50.7 100.0 42.4 42.4 0.5 7.7 8.2 The portfolio attribution data shown above is provided by FactSet based on information provided by Vanguard about the fund's daily portfolio holdings as of the market close. Because the fund buys and sells stocks throughout the trading day and not necessarily at the market close, the attribution data shown above is an estimate and may not precisely reflect actual attribution information. Information noted above does not reflect fair-value adjustments to prices of foreign securities held in the portfolio.
Top contributors—3 month Top detractors—3 month 3 mo. Total Ending Bench 3 mo. Total Ending Bench return effect weight weight return effect weight weight Eli Lilly and Company 23.4 0.5 4.7 0.5 Sony Group Corporation -8.3 -0.3 1.6 0.0 AstraZeneca PLC 20.5 0.3 2.8 0.0 NVIDIA Corporation 49.9 -0.3 0.2 1.2 Biogen Inc. 23.8 0.3 3.2 0.1 Siemens AG -3.7 -0.3 2.1 0.0 Johnson & Johnson 0.9 0.1 0.0 1.1 Amgen Inc. -1.3 -0.3 2.9 0.4 Elanco Animal Health Inc. 17.8 0.1 1.2 0.0 Southwest Airlines Co. -13.1 -0.7 3.0 0.1
Top contributors—12 month Top detractors—12 month 12 mo. Total Ending Bench 12 mo. Total Ending Bench return effect weight weight return effect weight weight FedEx Corporation 115.0 0.8 2.1 0.2 Intel Corporation -3.7 -0.4 1.7 0.6 KLA Corporation 69.0 0.6 2.0 0.1 Biogen Inc. 29.4 -0.5 3.2 0.1 Applied Materials Inc. 138.9 0.6 1.4 0.3 Novartis AG 7.1 -0.7 1.4 0.0 QUALCOMM Incorporated 59.8 0.5 0.8 0.4 AstraZeneca PLC 16.3 -1.0 2.8 0.0 L Brands Inc. 382.5 0.5 0.4 0.0 Amgen Inc. 4.2 -1.2 2.9 0.4
As of June 30, 2021 Vanguard PRIMECAP Core Fund
As of June 30, 2021 Important information For more information about Vanguard funds or Vanguard ETFs, visit vanguard.com or call 800-523-1036 to obtain a prospectus or, if available, a summary prospectus. Investment objectives, risks, charges, expenses, and other important information are contained in the prospectus; read and consider it carefully before investing.
Vanguard ETF Shares are not redeemable with the issuing Fund other than in very large aggregations worth millions of dollars. Instead, investors must buy or sell Vanguard ETF Shares in the secondary market and hold those shares in a brokerage account. In doing so, the investor may incur brokerage commissions and may pay more than net asset value when buying and receive less than net asset value when selling.
All investing is subject to risk, including the possible loss of the money you invest. Investments in bond funds and ETFs are subject to interest rate, credit, and inflation risk. Factor funds are subject to investment style risk, which is the chance that returns from the types of stocks in which the fund invests will trail returns from the stock market. Factor funds are subject to manager risk, which is the chance that poor security selection will cause the fund to underperform relevant benchmarks or other funds with a similar investment objective. Vanguard Commodity Strategy Fund could lose all, or substantially all, of its investments in instruments linked to the returns of commodity futures or other commodity investments. Commodity futures trading is volatile, and even a small movement in market prices could cause large losses. Investments in derivatives may involve risks different from, and possibly greater than, those of investments in the underlying securities or assets. London Stock Exchange Group companies includes FTSE International Limited (“FTSE”), Frank Russell Company (“Russell”), MTS Next Limited (“MTS”), and FTSE TMX Global Debt Capital Markets Inc (“FTSE TMX”). All rights reserved. “FTSE®”, “Russell®”, “MTS®”, “FTSE TMX®” and “FTSE Russell” and other service marks and trademarks related to the FTSE or Russell indexes are trade marks of the London Stock Exchange Group companies and are used by FTSE, MTS, FTSE TMX and Russell under licence. All information is provided for information purposes only. No responsibility or liability can be accepted by the London Stock Exchange Group companies nor its licensors for any errors or for any loss from use of this publication. Neither the London Stock Exchange Group companies nor any of their licensors make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to the results to be obtained from the use of the index or the fitness or suitability of the index for any particular purpose to which it might be put. The funds or securities referred to herein are not sponsored, endorsed, or promoted by MSCI, and MSCI bears no liability with respect to any such funds or securities. For any such funds or securities, the prospectus or the Statement of Additional Information contains a more detailed description of the limited relationship MSCI has with The Vanguard Group and any related funds. The index is a product of S&P Dow Jones Indices LLC (“SPDJI”), and has been licensed for use by Vanguard. Standard & Poor’s® and S&P® are registered trademarks of Standard & Poor’s Financial Services LLC (“S&P”); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”); S&P® and S&P 500® are trademarks of S&P; and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by Vanguard. Vanguard product(s) are not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, or their respective affiliates and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the index. The Russell Indexes and Russell® are registered trademarks of Russell Investments and have been licensed for use by The Vanguard Group. The products are not sponsored, endorsed, sold or promoted by Russell Investments and Russell Investments makes no representation regarding the advisability of investing in the products. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. “Dividend Achievers”is a trademark of The NASDAQ OMX Group, Inc. (collectively, with its affiliates, “NASDAQ OMX”) and has been licensed for use by The Vanguard Group, Inc. Vanguard mutual funds are not sponsored, endorsed, sold, or promoted by NASDAQ OMX and NASDAQ OMX makes no representation regarding the advisability of investing in the funds. NASDAQ OMX MAKES NO WARRANTIES AND BEARS NO LIABILITY WITH RESPECT TO THE VANGUARD MUTUAL FUNDS. BLOOMBERG® is a trademark and service mark of Bloomberg Finance L.P. BARCLAYS® is a trademark and service mark of Barclays Bank Plc, used under license. Bloomberg Finance L.P. and its affiliates, including Bloomberg Index Services Limited ("BISL") (collectively, "Bloomberg"), or Bloomberg's licensors own all proprietary rights in the Bloomberg Barclays Indices. The products are not sponsored, endorsed, issued, sold or promoted by “Bloomberg or Barclays”. Bloomberg and Barclays make no representation or warranty, express or implied, to the owners or purchasers of the products or any member of the public regarding the advisability of investing in securities generally or in the products particularly or the ability of the Bloomberg Barclays Indices to track general bond market performance. Neither Bloomberg nor Barclays has passed on the legality or suitability of the products with respect to any person or entity. Bloomberg’s only relationship to Vanguard and the products are the licensing of the Bloomberg Barclays Indices which are determined, composed and calculated by BISL without regard to Vanguard or the products or any owners or purchasers of the products. Bloomberg has no obligation to take the needs of the products or the owners of the products into consideration in determining, composing or calculating the Bloomberg Barclays Indices. Neither Bloomberg nor Barclays is responsible for and has not participated in the determination of the timing of, prices at, or quantities of the products to be issued. Neither Bloomberg nor Barclays has any obligation or liability in connection with the administration, marketing or trading of the products. Bloomberg Finance L.P. and its affiliates (collectively, “Bloomberg”) are not affiliated with Vanguard and do not approve, endorse, review, or recommend Vanguard Commodity Strategy Fund. BLOOMBERG and the Bloomberg Commodity Index are trademarks or service marks of Bloomberg and have been licensed to Vanguard. Bloomberg does not guarantee the timeliness, accurateness, or completeness of any data or information relating to the Bloomberg Commodity Index. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard and Poor's, a division of McGraw-Hill Companies, Inc. ("S&P") and is licensed for use by Vanguard. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classification makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of its affiliates or any third party involved in making or compiling the GICS or any GICS classification have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. CGS identifiers have been provided by CUSIP Global Services, managed on behalf of the American Bankers Association by Standard & Poor’s Financial Services, LLC, and are not for use or dissemination in a manner that would serve as a substitute for any CUSIP service. The CUSIP Database, © 2021 American Bankers Association. “CUSIP” is a registered trademark of the American Bankers Association. U.S. government backing of Treasury or agency securities applies only to the underlying securities and does not prevent share-price fluctuations. Unlike stocks and bonds, U.S. Treasury bills are guaranteed as to the timely payment of principal and interest. Investments in stocks or bonds issued by non-U.S. companies are subject to risks including country/regional risk and currency risk. Investments in Target Retirement Funds are subject to the risks of their underlying funds. The year in the Fund name refers to the approximate year (the target date) when an investor in the Fund would retire and leave the work force. The Fund will gradually shift its emphasis from more aggressive investments to more conservative ones based on its target date. An investment in the Target Retirement Fund is not guaranteed at any time, including on or after the target date. Center for Research in Security Prices, LLC (CRSP®) and its third-party suppliers have exclusive proprietary rights in the CRSP® Index Data, which has been licensed for use by Vanguard but is and shall remain valuable intellectual property owned by, and/or licensed to, CRSP®. The Vanguard Funds are not sponsored, endorsed, sold or promoted by CRSP®, The University of Chicago, or The University of Chicago Booth School of Business and neither CRSP®, The University of Chicago, or The University of Chicago Booth School of Business, make any representation regarding the advisability of investing in the Vanguard Funds.
© 2021 The Vanguard Group, Inc. All rights reserved. Managed Payout Fund U.S. Patent Nos. 8,180,695; 8,185,464; and 8,571,963. Vanguard ETFs U.S. Patent Nos. 6,879,964; 7,337,138; 7,720,749; 7,925,573; 8,090,646; 8,417,623; and 8,626,636. Vanguard Marketing Corporation, Distributor.